ey0019.12-9 | Metabolic syndrome | ESPEYB19
BN Ferguson D, Finck
Nat Rev Endocrinol 2021;17(8):484-95. doi: 10.1038/s41574-021-00507-zBrief Summary: This article reviews the results of clinical trials for modulators of glucagon-like peptide-1 (GLP1) activity, insulin-sensitizing thiazolidinediones, and inhibitors of the sodium-glucose cotransporter 2 (SGLT2) for the treatment of NAFLD and type 2 diabetes mellitus.Comment: NAFLD ha...